Jan 09, 2023 / 05:00PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott, diversified biopharma analyst at JPMorgan, and it's my pleasure to be introducing Regeneron this morning. Representing the company, we have the company's cofounders, CEO, Len Schleifer; as well as CSO, George Yancopoulos. 2022 was obviously a very successful year for Regeneron with the company making significant progress across its core drivers as well as its pipeline, and we're very much looking forward to an update as how the team is thinking about 2023 and beyond. So with that, I'll turn it over to Len.
Leonard S. Schleifer - Regeneron Pharmaceuticals, Inc. - Founder, President, CEO & Director
Hello, and good morning to everybody. It is really good to be here face-to-face. There I say virus to virus or variant to variant. I hope not. Anyway, we've got a lot we want to cover. So I'm going to jump right in. I'm Len Schleifer, and this is our forward-looking statement. We'll be making a bunch of forward-looking statements. So
Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers